Dr. Albala on financial implications of emergence of PSMA-PET imaging

“What’s important is that we get these studies approved so that our patients aren’t suffering any further economic burdens by having this new type of imaging being put forward,” says David Albala, MD.

In this video, urologist David Albala, MD, explains financial issues related to the emergence of PSMA-PET imaging as a critical component of the prostate cancer management paradigm. Albala is discussing PSMA-PET imaging during the CME program at the 2022 LUGPA Annual Meeting. He is a urologist at Associated Medical Professionals in Syracuse, New York.